Evidence map›Paper›PMID 29484112›Full record

ArticleOncotarget2018

Evidence that PP2A activity is dispensable for spindle assembly checkpoint-dependent control of Cdk1.

Nando Cervone, Rosa Della Monica, Angela Flavia Serpico, Cinzia Vetrei, Mario Scaraglio, Roberta Visconti, Domenico Grieco

Open access · diamondAbstract read
In one paragraph

Article in Oncotarget, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.1field-weighted citation impact, top 49% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Nando CervoneCEINGE Biotecnologie Avanzate, 80145 Naples, Italy.
Rosa Della MonicaCEINGE Biotecnologie Avanzate, 80145 Naples, Italy.
Angela Flavia SerpicoCEINGE Biotecnologie Avanzate, 80145 Naples, Italy.
Cinzia VetreiCEINGE Biotecnologie Avanzate, 80145 Naples, Italy.
Mario ScaraglioCEINGE Biotecnologie Avanzate, 80145 Naples, Italy.
Roberta ViscontiIEOS, CNR, 80131 Naples, Italy.
Domenico GriecoCEINGE Biotecnologie Avanzate, 80145 Naples, Italy.
University of Naples Federico II · ITCeinge Biotecnologie Avanzate (Italy) · ITInstitute for Experimental Endocrinology and Oncology · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Progression through mitosis, the cell cycle phase deputed to segregate replicated chromosomes, is granted by a protein phosphorylation wave that follows an activation-inactivation cycle of cyclin B-dependent kinase (Cdk) 1, the major mitosis-promoting enzyme. To ensure correct chromosome segregation, the safeguard mechanism spindle assembly checkpoint (SAC) delays Cdk1 inactivation by preventing cyclin B degradation until mitotic spindle assembly. At the end of mitosis, reversal of bulk mitotic protein phosphorylation, downstream Cdk1 inactivation, is required to complete mitosis and crucially relies on the activity of major protein phosphatases like PP2A. A role for PP2A, however, has also been suggested in spindle assembly and SAC-dependent control of Cdk1. Indeed, PP2A was found in complex with SAC proteins while small interfering RNAs (siRNAs)-mediated downregulation of PP2A holoenzyme components affected mitosis completion in mammalian cells. However, whether the SAC-dependent control of Cdk1 required the catalytic activity of PP2A has never been directly assessed. Here, using two PP2A inhibitors, okadaic acid and LB-100, we provide evidence that PP2A activity is dispensable for SAC control of Cdk1 in human cells.

Indexed as

PP1PP2Aprotein phosphataseSACspindle assembly checkpoint

Identifiers

PMID29484112
PMCPMC5800904
OpenAlexW2774479973

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.